生物制剂与炎症性肠病恶性肿瘤发生风险关系的研究进展  

Progress in understanding of relationship between use of biological agents and risk of malignant tumors in patients with inflammatory bowel disease

作　　者：毛雨晴 孙少鹏 吕宾[1] 范一宏[1] Yu-Qing Mao;Shao-Peng Sun;Bin Lv;Yi-Hong Fan(Department of Gastroenterology,The First Affiliated Hospital of Zhejiang Chinese Medical University,Hangzhou 310003,Zhejiang Province,China)

机构地区：[1]浙江中医药大学附属第一医院消化内科,浙江省杭州市310003

出　　处：《世界华人消化杂志》2024年第3期221-227,共7页World Chinese Journal of Digestology

基　　金：浙江省中医药科技计划,No.2019ZA056、No.2022ZB129和No.2021ZA057;浙江省医药卫生厅科技计划项目,No.2023KY864.

摘　　要：炎症性肠病(inflammation bowel disease,IBD)作为一种慢性疾病需终身治疗,使用生物制剂开展靶向治疗是当前IBD的主要治疗方法.随着IBD合并恶性肿瘤患者的逐渐增多,生物制剂与IBD患者恶性肿瘤的发生风险之间的关系日益引起关注.本文对生物制剂的使用与否与IBD患者恶性肿瘤的发生和发展风险进行综述,以期为IBD患者的临床用药决策提供参考.Inflammatory bowel disease(IBD)is a chronic disease that requires lifelong treatment,and targeted therapy with biological agents is currently the main treatment method for IBD.With the increasing number of IBD patients with malignant tumors,the relationship between biological agents and the risk of malignant tumors in IBD patients is attracting increasing attention.This article reviews the relationship between the use of biological agents and the risk of malignant tumor occurrence and development in IBD patients,with the aim of providing reference for clinical medication decisions in IBD patients.

关 键 词：生物制剂 恶性肿瘤 炎症性肠病 溃疡性结肠炎 克罗恩病 抗肿瘤坏死因子 

分 类 号：R574[医药卫生—消化系统]